Altimmune Inc. (ALT) News Headlines

▮ More

Date

Headline

5/19/2022 7:32:13 AM Pre-market Movers: CIG, NOVN, INO, BGXX, CSCO…

4/1/2022 7:13:45 AM Altimmune Begins 48-week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity

1/31/2022 7:15:48 AM Altimmune: FDA Clears IND Application For Phase 2 Clinical Trial Of Pemvidutide For Obesity

12/13/2021 6:23:58 AM Altimmune Appoints Richard Eisenstadt As Chief Financial Officer - Quick Facts

12/13/2021 6:09:19 AM Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12/13/2021 6:08:48 AM Altimmune Appoints Richard Eisenstadt As CFO, Effective Dec 31

10/4/2021 7:23:51 AM Altimmune Begins 12-week Phase 1b Trial Of Pemvidutide In Subjects With Non-Alcoholic Fatty Liver Disease

9/28/2021 10:51:58 AM Altimmune Shares Tank 20% After Announcing Phase 1 Results From Weight Loss Treatment Trial

9/28/2021 8:10:27 AM Altimmune : Subjects Receiving ALT-801 Achieves Mean Weight Loss Of 10.3% At 1.8 Mg Dose; Stock Down

9/28/2021 7:27:37 AM Altimmune Announces Positive Results From 12-week Phase 1 Trial Of Pemvidutide In Overweight And Obese Volunteers

9/27/2021 5:02:56 PM Altimmune To Report Results Of Obesity Treatment On Sept. 28

6/29/2021 5:24:00 PM Altimmune Tanks 35% After It Discontinues Covid-19 Vaccine Development

6/16/2021 7:13:09 AM Altimmune Announces Positive Interim Data From ALT-801 Phase 1 Trial In Healthy Overweight And Obese Volunteers

5/26/2021 9:29:13 AM Altimmune's AdCOVID Neutralizes South African Variant In Preclinical Study

Older Articles